LENZ Therapeutics, Inc. SEC filings LENZ
LENZ Therapeutics, Inc. has 359 filings in SEC EDGAR's recent list, going back to Mar 19, 2021. Its latest annual report, Form ARS, was filed on Apr 28, 2026 for the period ended Dec 31, 2025. The latest quarterly report (Form 10-Q) was filed on Nov 3, 2026, covering the quarter ended Sep 30, 2026. The most recent current report (Form 8-K) was filed on Oct 28, 2026 (results of operations, exit or restructuring costs, officer or director change). The company's fiscal year ends on December 31.
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Results of operations, Exit or restructuring costs, Officer or director change
|
Oct 28, 2026 | Oct 28, 2026 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2026 | Aug 11, 2026 |
| 8-K |
Current report
Officer or director change
|
Jul 2, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Shareholder vote results
|
Jun 12, 2026 | Jun 12, 2026 |
| 8-K |
Current report
Results of operations
|
May 11, 2026 | May 11, 2026 |
| 8-K |
Current report
Results of operations
|
Mar 24, 2026 | Mar 24, 2026 |
| 8-K |
Current report
Results of operations
|
Jan 7, 2026 | Jan 7, 2026 |
| 8-K |
Current report
Other events
|
Dec 12, 2025 | Dec 12, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 5, 2025 | Nov 5, 2025 |
| 8-K |
Current report
Other events
|
Oct 8, 2025 | Oct 8, 2025 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Sep 30, 2025 | Sep 30, 2025 |
| 8-K |
Current report
Other events
|
Jul 31, 2025 | Jul 31, 2025 |
| 8-K |
Current report
Results of operations
|
Jul 30, 2025 | Jul 30, 2025 |
| 8-K |
Current report
Shareholder vote results
|
Jun 10, 2025 | Jun 10, 2025 |
| 8-K |
Current report
Results of operations
|
May 7, 2025 | May 7, 2025 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure, Other events
|
Apr 15, 2025 | Apr 15, 2025 |
| 8-K |
Current report
Material agreement
|
Apr 4, 2025 | Apr 4, 2025 |
| 8-K |
Current report
Results of operations
|
Mar 19, 2025 | Mar 19, 2025 |
| 8-K |
Current report
Results of operations
|
Nov 6, 2024 | Nov 6, 2024 |
| 8-K |
Current report
Other events
|
Oct 28, 2024 | Oct 27, 2024 |
| 8-K |
Current report
Results of operations
|
Aug 14, 2024 | Aug 14, 2024 |
| 8-K |
Current report
Other events
|
Aug 12, 2024 | Aug 12, 2024 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Regulation FD disclosure
|
Jul 15, 2024 | Jul 14, 2024 |
| 8-K |
Current report
Results of operations
|
May 8, 2024 | May 8, 2024 |
| 8-K |
Current report
Other events
|
Apr 3, 2024 | Apr 3, 2024 |
| 8-K |
Current report
Acquisition or sale of assets, Unregistered share sale, Change to shareholder rights, Auditor change, Change in control, Officer or director change, Bylaw or fiscal year change, Regulation FD disclosure
|
Mar 22, 2024 | Mar 21, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 19, 2024 | Mar 19, 2024 |
| 8-K |
Current report
Shareholder vote results
|
Mar 14, 2024 | Mar 14, 2024 |
| 8-K |
Current report
Regulation FD disclosure
|
Mar 8, 2024 | Mar 8, 2024 |
| 8-K |
Current report
Other events
|
Mar 5, 2024 | Mar 5, 2024 |
| 8-K |
Current report
Other events
|
Dec 26, 2023 | Dec 21, 2023 |
| 8-K |
Current report
Material agreement, Unregistered share sale, Change in control, Officer or director change, Regulation FD disclosure
|
Nov 15, 2023 | Nov 14, 2023 |
| 8-K |
Current report
Material agreement
|
Oct 30, 2023 | Oct 26, 2023 |
| 8-K/A |
Amended current report
Officer or director change
|
Sep 13, 2023 | Aug 18, 2023 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Aug 23, 2023 | Aug 18, 2023 |
| 8-K |
Current report
Officer or director change
|
Aug 2, 2023 | Jul 28, 2023 |
| 8-K |
Current report
Shareholder vote results
|
Jul 20, 2023 | Jul 19, 2023 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Jun 23, 2023 | Jun 23, 2023 |
| 8-K |
Current report
Results of operations
|
Mar 20, 2023 | Mar 20, 2023 |
| 8-K |
Current report
Officer or director change
|
Mar 16, 2023 | Mar 10, 2023 |
| 8-K |
Current report
Exit or restructuring costs, Officer or director change, Other events
|
Feb 22, 2023 | Feb 16, 2023 |
| 8-K |
Current report
Other events
|
Jan 5, 2023 | Jan 5, 2023 |
| 8-K |
Current report
Other events
|
Dec 12, 2022 | Dec 11, 2022 |
| 8-K |
Current report
Results of operations
|
Nov 9, 2022 | Nov 9, 2022 |
| 8-K |
Current report
Other events
|
Nov 3, 2022 | Nov 3, 2022 |
| 8-K |
Current report
Results of operations
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K |
Current report
Other events
|
Aug 11, 2022 | Aug 11, 2022 |
| 8-K/A |
Amended current report
Other events
|
Jul 13, 2022 | May 16, 2022 |
| 8-K |
Current report
Shareholder vote results
|
Jun 23, 2022 | Jun 21, 2022 |
| 8-K |
Current report
Results of operations
|
May 16, 2022 | May 16, 2022 |
| 8-K |
Current report
Results of operations
|
May 12, 2022 | May 12, 2022 |
| 8-K |
Current report
Results of operations
|
Mar 21, 2022 | Mar 21, 2022 |
| 8-K |
Current report
Officer or director change
|
Mar 2, 2022 | Mar 2, 2022 |
| 8-K |
Current report
Material agreement, New debt
|
Dec 20, 2021 | Dec 16, 2021 |
| 8-K |
Current report
Officer or director change
|
Dec 8, 2021 | Dec 6, 2021 |
| 8-K |
Current report
Regulation FD disclosure, Other events
|
Nov 17, 2021 | Nov 17, 2021 |
| 8-K |
Current report
Material agreement, New debt
|
Nov 16, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Nov 10, 2021 | Nov 10, 2021 |
| 8-K |
Current report
Results of operations
|
Aug 12, 2021 | Aug 12, 2021 |
| 8-K |
Current report
Material agreement, Bylaw or fiscal year change
|
Jun 30, 2021 | Jun 24, 2021 |
Showing 60 filings. Main filings leave out insider and ownership forms such as Form 4; choose a type above to see them. Each form opens on SEC.gov. Older filings are on SEC EDGAR.
New to this? Read What Are SEC Filings? 10-K, 10-Q, 8-K and Other Forms Explained.
Company profile
- Industry
- Biological Products, (No Diagnostic Substances) (SIC 2836)
- Listed as
- LENZ (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Solana Beach, CA
- SEC filer status
- Non-accelerated filer, Smaller reporting company, Emerging growth company
- SEC CIK
- 1815776
- Former names
- Graphite Bio, Inc. (until Mar 19, 2024)
Other Biological Products, (No Diagnostic Substances) companies
- Amgen Inc AMGN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Argenx SE ARGX
- Revolution Medicines, Inc. RVMD
- Biogen Inc. BIIB
- BioNTech SE BNTX
- Exelixis, Inc. EXEL
All 182 Biological Products, (No Diagnostic Substances) companies
Source: SEC EDGAR filings. This is company-reported data, not investment advice.